Clinical Trials Logo

Impaired Glucose Tolerance clinical trials

View clinical trials related to Impaired Glucose Tolerance.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03315663 Withdrawn - Prediabetes Clinical Trials

Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes - Main Study

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

Sweetch is a personalized mobile-health platform coaching system (mobile phone app) designed to promote adherence to physical activity guidelines for people with prediabetes.

NCT ID: NCT02472717 Withdrawn - Type 2 Diabetes Clinical Trials

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

PLAQUE
Start date: May 2015
Phase: Phase 2
Study type: Interventional

Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1 receptor) agonist on joint and skin inflammation in patients with active Psoriatic Arthritis.

NCT ID: NCT01093677 Withdrawn - Clinical trials for Impaired Glucose Tolerance

Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance

LIM
Start date: March 2010
Phase: Phase 1
Study type: Interventional

LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose Tolerance

NCT ID: NCT00845559 Withdrawn - Obesity Clinical Trials

The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

Start date: August 2008
Phase: Phase 4
Study type: Interventional

The primary aim of this study is to evaluate the effect of exenatide on daily glycemic excursions obtained by continuous glucose monitoring system (CGMS). The CGMS summary parameters that we are most interested in include: - The percent of glucose values above 140 mg/dl and/or AUC of glucose values above 140 mg/dl - AUC of glucose values over 100 mg/dl during three days - Maximal meal-related glucose excursions - Three-day mean glucose (including low readings - below 100 mg/dl) Secondary Study Endpoints: Secondary endpoints will include: - glucose tolerance status as assessed by OGTT - Vascular function scores as assessed by PAT, FMD and step test. - Biochemical markers of vascular health, including inflammatory markers, markers of oxidative stress and microalbuminuria. - Changes in BMI